Capital International, Inc. Cellectis S.A. Transaction History

Capital International, Inc.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	SELL	$8.01 - $12.84 $6.91 Million - $11.1 Million	-862,789 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$11.94 - $16.09 $153,357 - $206,659	-12,844 Reduced 1.47%	862,789 $10.9 Million
Q2 2021 Aug 16, 2021	SELL	$14.36 - $20.93 $539,907 - $786,926	-37,598 Reduced 4.12%	875,633 $13.5 Million
Q1 2021 May 14, 2021	SELL	$18.19 - $33.25 $766,817 - $1.4 Million	-42,156 Reduced 4.41%	913,231 $18.5 Million
Q4 2020 Feb 16, 2021	SELL	$15.87 - $31.64 $293,690 - $585,529	-18,506 Reduced 1.9%	955,387 $25.9 Million
Q3 2020 Nov 13, 2020	SELL	$15.7 - $20.84 $215,199 - $285,653	-13,707 Reduced 1.39%	973,893 $18 Million
Q1 2020 May 15, 2020	BUY	$7.81 - $18.82 $7.71 Million - $18.6 Million	987,600 New	987,600 $9.09 Million

10.8M

5.9K

1.4K

Ticker CLLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,510,800
Market Cap $74.6M
Description
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatm...

Get notified when there are updates to the investment portfolio of Capital International, Inc., based on Form 13F filings with the SEC.

Stay updated on Capital International, Inc. with notifications on news.